Amplitude Healthcare Acquisition Corporation
AMHC
NASDAQ Global Select10.23
USD
-0.42
- -
CIK
0001788028
ISIN
US03212A1051
CUSIP
03212A105
Return %
Stock
S&P500
1Y
- -
18.21
3Y
2.92
63.29
5Y
4.18
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Balaji Venkataraman
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1177 Avenue of the Americas Fl 40 New York City NY United States of America 10036
- IPO Date
- Nov 20, 2019
- CIK
- 0001788028
- Website
- amplitudehealthcare.com
- Similar Companies
- Business
- Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHC) operates as a blank check company whose purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, with a focus on healthcare and healthcare-related industries in the United States and Europe. Incorporated in 2019 and based in New York, New York, the company has not conducted substantive operations, generated revenue or identified any specific acquisition target; it maintains approximately two employees and holds funds primarily in trust for potential transactions. In 2021, AMHC entered a definitive business combination agreement with Jasper Therapeutics, Inc., a clinical-stage biotechnology company developing hematopoietic cell transplant therapies, which included a committed $100 million PIPE financing from investors such as Federated Hermes Kaufmann Funds, Avego, Metalmark Capital, Amgen and Roche Venture Fund; shareholders approved the transaction in September 2021 amid substantial redemptions, leading to its completion and Jasper's public listing under the ticker JSPR. No subsequent mergers, acquisitions, funding rounds, product launches or operational expansions have occurred in the last 1-2 years, and AMHC remains an inactive special purpose acquisition company without current business combinations or revenue-generating activities.
Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy
AMHC Stock: Why It Substantially Increased Today
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Amplitude Healthcare Acquisition Corp. - AMHC
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines